ATE527284T1 - Modifizierte antikörper-fragmente - Google Patents
Modifizierte antikörper-fragmenteInfo
- Publication number
- ATE527284T1 ATE527284T1 AT06764991T AT06764991T ATE527284T1 AT E527284 T1 ATE527284 T1 AT E527284T1 AT 06764991 T AT06764991 T AT 06764991T AT 06764991 T AT06764991 T AT 06764991T AT E527284 T1 ATE527284 T1 AT E527284T1
- Authority
- AT
- Austria
- Prior art keywords
- chi
- antibody fragments
- modified antibody
- chain constant
- region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514779.8A GB0514779D0 (en) | 2005-07-19 | 2005-07-19 | Biological products |
| PCT/GB2006/002649 WO2007010231A1 (en) | 2005-07-19 | 2006-07-17 | Modified antibody fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527284T1 true ATE527284T1 (de) | 2011-10-15 |
Family
ID=34897451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06764991T ATE527284T1 (de) | 2005-07-19 | 2006-07-17 | Modifizierte antikörper-fragmente |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8053562B2 (de) |
| EP (1) | EP1913026B1 (de) |
| JP (1) | JP2009501773A (de) |
| AT (1) | ATE527284T1 (de) |
| AU (1) | AU2006271416A1 (de) |
| CA (1) | CA2615485A1 (de) |
| ES (1) | ES2374222T3 (de) |
| GB (1) | GB0514779D0 (de) |
| WO (1) | WO2007010231A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| AU2008261042A1 (en) * | 2007-06-08 | 2008-12-11 | Dow Global Technologies Inc. | Expression of soluble antibody fragment by truncation of CH1 domain |
| BRPI0907046A2 (pt) * | 2008-01-18 | 2015-07-28 | Medimmune Llc | Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo |
| NZ594315A (en) | 2009-02-17 | 2013-05-31 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| WO2011118739A1 (ja) | 2010-03-26 | 2011-09-29 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
| RS60499B1 (sr) * | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
| RU2016122041A (ru) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| SG11201604664PA (en) | 2013-12-12 | 2016-07-28 | Stemcentrx Inc | Novel anti-dpep3 antibodies and methods of use |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
| KR102669686B1 (ko) * | 2015-04-28 | 2024-05-29 | 자임워크스 비씨 인코포레이티드 | 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| CN109475627B (zh) | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| CN110177805B (zh) | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| JP2019534044A (ja) | 2016-11-08 | 2019-11-28 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗pd1および抗ctla4抗体 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP2024527977A (ja) | 2021-07-27 | 2024-07-26 | ノヴァブ, インコーポレイテッド | 免疫エフェクター機能を有する操作されたvlrb抗体 |
| WO2024227427A1 (en) * | 2023-04-29 | 2024-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Modified antibodies, antibody fragments thereof, and antibody-drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| ES2331909T3 (es) * | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
| PT1495056E (pt) | 2002-03-20 | 2011-03-29 | Ucb Pharma Sa | Métodos de análise |
| PT1558643E (pt) * | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2004106375A1 (en) * | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1737890A2 (de) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulinvarianten ausserhalb der fc-region |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
-
2005
- 2005-07-19 GB GBGB0514779.8A patent/GB0514779D0/en not_active Ceased
-
2006
- 2006-07-17 US US11/995,740 patent/US8053562B2/en not_active Expired - Fee Related
- 2006-07-17 AT AT06764991T patent/ATE527284T1/de not_active IP Right Cessation
- 2006-07-17 ES ES06764991T patent/ES2374222T3/es active Active
- 2006-07-17 AU AU2006271416A patent/AU2006271416A1/en not_active Abandoned
- 2006-07-17 EP EP06764991A patent/EP1913026B1/de active Active
- 2006-07-17 WO PCT/GB2006/002649 patent/WO2007010231A1/en not_active Ceased
- 2006-07-17 JP JP2008522049A patent/JP2009501773A/ja not_active Withdrawn
- 2006-07-17 CA CA002615485A patent/CA2615485A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006271416A1 (en) | 2007-01-25 |
| WO2007010231A1 (en) | 2007-01-25 |
| GB0514779D0 (en) | 2005-08-24 |
| CA2615485A1 (en) | 2007-01-25 |
| ES2374222T3 (es) | 2012-02-14 |
| EP1913026B1 (de) | 2011-10-05 |
| JP2009501773A (ja) | 2009-01-22 |
| EP1913026A1 (de) | 2008-04-23 |
| US8053562B2 (en) | 2011-11-08 |
| US20080269466A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE527284T1 (de) | Modifizierte antikörper-fragmente | |
| WO2005003169A3 (en) | Modified antibody fab fragments | |
| WO2005003171A3 (en) | Modified antibody fragments | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| NO20074563L (no) | Novel anti-plgf antibody | |
| GB201005064D0 (en) | Biological products | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| NO20085408L (no) | Protease screeningmetoder og proteaser identifisert derved | |
| DK2074143T3 (da) | Ændrede antistoffer | |
| CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
| ATE525392T1 (de) | Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| CY1114350T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| ATE484749T1 (de) | Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| DE602006007967D1 (de) | Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon | |
| EA200702193A1 (ru) | Гликозилирование белков | |
| EA200701592A1 (ru) | Композиты и способы их получения и использования | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
| MX2009013393A (es) | Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1. | |
| MX2024002728A (es) | Polipeptidos. | |
| CY1112194T1 (el) | Μεθοδοι για ρυθμιση φωτοτοξικοτητας | |
| UA111322C2 (uk) | Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування | |
| TH148296A (th) | แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |